Clinical trial · Observational
A Transfer Learning Radiomics Model for Predicting Response to Initial Transarterial Embolization in Patients with Gastroenteropancreatic Neuroendocrine Tumor Liver Metastases
A Transfer Learning Radiomics Model for Predicting Response to Initial Transarterial Embolization in Patients with Gastroenteropancreatic Neuroendocrine Tumor Liver Metastases: from Lesion-targeted to Patient-targeted Prediction
NCT06853457CI-TRIAL-00086664completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To develop and validate a CT-based transfer learning radiomics model for predicting response to initial TAE in GEP-NETLM patients and compare its performance with traditional radiomics and clinical models.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neuroendocrine Tumors, NET | Neuroendocrine Tumor | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- training set
- description
- The training set consisted of patients from January 2014 to December 2020.
- label
- testing set
- description
- the testing set included patients from January 2021 to September 2022.
Primary outcomes (1)
- measure
- The efficacy of TAE
- timeFrame
- Within one month prior and 4-6 weeks following the initial TAE.
- description
- Complete multiphase contrast-enhanced CT images were collected preoperatively and postoperatively. The efficacy of TAE was assessed based on RECIST 1.1 criteria. Patients were classified as objective responders (those achieving complete response \[CR\] or partial response \[PR\]) or non-responders (those with stable disease \[SD\] or progressive disease \[PD\]) through evaluation of target lesions.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 78 Years
Show eligibility criteria text
Inclusion Criteria: * (a) Clinical diagnosed as gastroenteropancreatic neuroendocrine tumor liver metastases; (b) Received initial transarterial embolization therapy; (c) Underwent multi-phase ceCT scans pre-TAE (≤1 month) and post-TAE (4-6 weeks). Exclusion Criteria: * (a) Neuroendocrine carcinoma (NEC) or other malignancies. (b) Received other liver metastasis treatments. (c) Lack of Multi-phase ceCT scans records. (d) CT images with artifacts or no visible lesions.
References
Publications (0)
Data not yet available
No reference posted for this study.